AU2019299352B2 - Ivosidenib forms and pharmaceutical compositions - Google Patents

Ivosidenib forms and pharmaceutical compositions Download PDF

Info

Publication number
AU2019299352B2
AU2019299352B2 AU2019299352A AU2019299352A AU2019299352B2 AU 2019299352 B2 AU2019299352 B2 AU 2019299352B2 AU 2019299352 A AU2019299352 A AU 2019299352A AU 2019299352 A AU2019299352 A AU 2019299352A AU 2019299352 B2 AU2019299352 B2 AU 2019299352B2
Authority
AU
Australia
Prior art keywords
ivosidenib
pharmaceutical composition
solvent
rule
substitute sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019299352A
Other languages
English (en)
Other versions
AU2019299352A1 (en
Inventor
Chong-Hui Gu
Jacob Paul Sizemore
Shijie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2019299352A1 publication Critical patent/AU2019299352A1/en
Assigned to LES LABORATORIES SERVIER reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: AGIOS PHARMACEUTICALS, INC.
Assigned to LES LABORATOIRES SERVIER reassignment LES LABORATOIRES SERVIER Amend patent request/document other than specification (104) Assignors: LES LABORATORIES SERVIER
Application granted granted Critical
Publication of AU2019299352B2 publication Critical patent/AU2019299352B2/en
Priority to AU2025203835A priority Critical patent/AU2025203835A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019299352A 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions Active AU2019299352B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203835A AU2025203835A1 (en) 2018-07-06 2025-05-23 Ivosidenib forms and pharmaceutical compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
US62/694,596 2018-07-06
PCT/US2019/040257 WO2020010058A1 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203835A Division AU2025203835A1 (en) 2018-07-06 2025-05-23 Ivosidenib forms and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2019299352A1 AU2019299352A1 (en) 2021-01-07
AU2019299352B2 true AU2019299352B2 (en) 2025-02-27

Family

ID=69059942

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019299352A Active AU2019299352B2 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions
AU2025203835A Pending AU2025203835A1 (en) 2018-07-06 2025-05-23 Ivosidenib forms and pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203835A Pending AU2025203835A1 (en) 2018-07-06 2025-05-23 Ivosidenib forms and pharmaceutical compositions

Country Status (18)

Country Link
US (1) US12264148B2 (https=)
EP (2) EP3817744A4 (https=)
JP (2) JP7621242B2 (https=)
KR (2) KR102919157B1 (https=)
CN (1) CN112367995A (https=)
AU (2) AU2019299352B2 (https=)
BR (1) BR112021000156A2 (https=)
CA (1) CA3103498A1 (https=)
EA (1) EA202190217A1 (https=)
IL (2) IL315423B1 (https=)
MA (1) MA53099A (https=)
MX (2) MX2021000068A (https=)
PH (1) PH12021550017A1 (https=)
SG (1) SG11202012763TA (https=)
TW (2) TWI902665B (https=)
UA (1) UA129800C2 (https=)
WO (1) WO2020010058A1 (https=)
ZA (1) ZA202008034B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010331T (pt) 2019-08-08 2024-01-08 Servier Lab Um método de preparação do ivosidenib e de um seu intermediário
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138839A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
RU2013144975A (ru) * 2011-04-08 2015-05-20 Пфайзер Инк. Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
BR122023021436A2 (pt) * 2014-03-14 2023-12-12 Les Laboratoires Servier Formas cristalinas e composição farmacêutica de compostos terapeuticamente ativos
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
ES2912909T3 (es) * 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
WO2019104318A1 (en) 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138839A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds

Also Published As

Publication number Publication date
TW202019419A (zh) 2020-06-01
TWI902665B (zh) 2025-11-01
EP4603147A2 (en) 2025-08-20
JP2021529805A (ja) 2021-11-04
JP2024150784A (ja) 2024-10-23
SG11202012763TA (en) 2021-02-25
MA53099A (fr) 2021-05-12
EP4603147A3 (en) 2025-10-01
IL279877A (en) 2021-03-01
TW202543623A (zh) 2025-11-16
BR112021000156A2 (pt) 2021-04-06
MX2021000068A (es) 2021-03-25
KR20210029775A (ko) 2021-03-16
US20210323944A1 (en) 2021-10-21
IL315423B1 (en) 2026-04-01
EA202190217A1 (ru) 2021-04-16
CN112367995A (zh) 2021-02-12
AU2025203835A1 (en) 2025-06-12
JP7621242B2 (ja) 2025-01-24
TWI911130B (zh) 2026-01-01
MX2023011687A (es) 2023-10-19
AU2019299352A1 (en) 2021-01-07
UA129800C2 (uk) 2025-08-06
KR20250164882A (ko) 2025-11-25
ZA202008034B (en) 2021-10-27
CA3103498A1 (en) 2020-01-09
PH12021550017A1 (en) 2021-09-13
WO2020010058A1 (en) 2020-01-09
EP3817744A1 (en) 2021-05-12
US12264148B2 (en) 2025-04-01
IL315423A (en) 2024-11-01
EP3817744A4 (en) 2022-07-13
KR102919157B1 (ko) 2026-01-27

Similar Documents

Publication Publication Date Title
AU2019246824B2 (en) Pharmaceutical compositions of therapeutically active compounds and their methods of use
AU2019232825B2 (en) Pharmaceutical compositions of therapeutically active compounds
AU2025203835A1 (en) Ivosidenib forms and pharmaceutical compositions
HK40129554A (en) Ivosidenib forms and pharmaceutical compositions
EA048347B1 (ru) Формы ивосидениба и фармацевтические композиции
EA053032B1 (ru) Формы ивосидениба и фармацевтические композиции
HK40044696A (en) Pharmaceutical compositions of therapeutically active compounds and uses thereof
HK1233185B (en) Pharmaceutical compositions of therapeutically active compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER APPLICANT(S): AGIOS PHARMACEUTICALS, INC.

HB Alteration of name in register

Owner name: LES LABORATOIRES SERVIER

Free format text: FORMER NAME(S): LES LABORATORIES SERVIER

FGA Letters patent sealed or granted (standard patent)